PharmaMar’s Zepsyre® ATLANTIS trial in small-cell lung cancer will be an oral presentation at the IASLC's Targeted Therapies annual meeting

Madrid, February 20th, 2019 PharmaMar’s (MSE:PHM) clinical trial of Zepsyre® (lurbinectedin) in combination with doxorubicin in relapsed small-cell lung cancer patients will be presented at an oral session at the 19th annual meeting on Targeted Therapies in Lung Cancer that is organized by the International Association for the Study of Lung Cancer (IASLC), taking place in in Santa Monica, California, from the 20th to the 23rd of February 2019. This specialized meeting is designed to provide information about ongoing clinical trials of the newest and most promising therapies for lung cancer.

The presentation will be on Thursday February 21st, at 10:25 Pacific time, by Dr. William J. Petty, Director, Thoracic Oncology Program, Professor of Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine.

Zepsyre® (lurbinectedin) is currently awaiting results after final analysis during 2019, from two trials that both completed recruitment in 2018. The multi-center basket trial cohort in relapsed small-cell lung cancer that recruited 105 patients to be treated with Zepsyre® monotherapy and it is hoped that results are presented at a future congress on oncology.

In addition, the randomized multi-center ATLANTIS phase III clinical trial that enrolled 613 patients with relapsed small cell lung cancer to be treated with either Zepsyre® in combination with doxorubicin versus    Topotecan or CAV, is due to report top line results around year end 2019. 

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

 

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several ty-pes of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical enterprise, Zelnova Zeltia. To learn more about PharmaMar, please visit us at www.pharmamar.com

About lurbinectedin

Lurbinectedin (PM1183) is a compound under clinical investigation. It is an inhibitor of RNA polymerase II. This enzyme is essential for the transcription process that is over-activated in tumors with transcription addiction.

 

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127

Miguel Martínez-Cava – Digital Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464

Phone: +34 918466000

Back to news